Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Sunrun Inc (RUN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Sunrun Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Sunrun Inc trades at $11.98 (market cap $2.91B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | RUN | |
|---|---|---|
Market Cap | $4.49B | $2.91B |
Sector | Health | Technology |
52-Week High | $28.06 | $21.41 |
52-Week Low | $20.06 | $9.07 |
Enterprise Value | $3.69B | $17.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Sunrun (RUN) trades at $12.97, up 1.81% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamental metrics with a low P/E of 6.09 and robust profitability margins, while recent news highlights the company's strategic partnership with Tesla for virtual power plants targeting AI data center demand. Cash flow trends show significant investing activity with positive net cash flow.
The outlook remains cautiously optimistic with analyst consensus at Buy (62%) and a $17.58 price target, though technical weakness and negative operating cash flow present near-term risks. The Tesla partnership offers growth potential in energy infrastructure, but execution risks and market volatility require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
